Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.
about
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysisTregalizumab - A Monoclonal Antibody to Target Regulatory T CellsBiologicals in rheumatoid arthritis: current and futureBiologic efficacy optimization--a step towards personalized medicineImmunogenicity of biologic agents in rheumatoid arthritis patients: lessons for clinical practiceRisk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studiesAdvances in the treatment of rheumatoid arthritis.Subcutaneous abatacept for the treatment of rheumatoid arthritis.Refining the Management of Rheumatoid Arthritis: the Benefits of Subcutaneous TocilizumabBiologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment.Risk of Tuberculosis Reactivation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Receiving Non-Anti-TNF-Targeted BiologicsImmune suppression in cynomolgus monkeys by XPro9523: an improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRnSubcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept.Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept.Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).A Nationwide Survey on Patient's versus Physician´s Evaluation of Biological Therapy in Rheumatoid Arthritis in Relation to Disease Activity and Route of Administration: The Be-Raise StudyHead-to-head comparison of aggressive conventional therapy and three biological treatments and comparison of two de-escalation strategies in patients who respond to treatment: study protocol for a multicenter, randomized, open-label, blinded-assessoHead-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK).Reductions in disease activity in the AMPLE trial: clinical response by baseline disease durationImmunogenicity of subcutaneously administered therapeutic proteins--a mechanistic perspective.Efficacy and Safety of Rituximab in Biologic-Naive Patients with Rheumatoid Arthritis vs Anti-Tnf Therapy Failure.Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritisIncidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature.Patient-Reported Outcomes From a Two-Year Head-to-Head Comparison of Subcutaneous Abatacept and Adalimumab for Rheumatoid Arthritis.Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial.Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs (MATSURI study).A critical evaluation of the role of subcutaneous abatacept in the treatment of rheumatoid arthritis: patient considerations.Self in vivo production of a synthetic biological drug CTLA4Ig using a minicircle vector.Current understanding of rheumatoid arthritis therapy.Evolution of treatment for rheumatoid arthritis.Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives.Abatacept: a review of its use in the management of rheumatoid arthritis.Update on the use of abatacept for the treatment of rheumatoid arthritis.Biosimilars: how similar?Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis.Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis.
P2860
Q24185797-2FC3E405-73AE-4549-B6C2-D275D43C0E45Q26772699-74C4458B-5775-4BF0-9490-F81AE35EE605Q26780316-30F29C0D-CF5A-4F2D-8683-2A7926516944Q26783657-2BDFA6FD-41C0-4296-8187-46028A0D55F1Q26798357-8491E66C-BB15-44B5-A7FA-9C554E65D648Q26991673-211237F1-3ED7-4E6C-AFA7-147EDE725FFBQ27691822-54639786-A070-4C8F-90BA-CB1159F8D7B4Q27692117-51C5FA84-8668-4210-8403-6C21439CAE3AQ28080677-4CC11A10-50D1-4691-9DC8-1660883C1801Q30234528-4CA67FA4-6106-403A-B677-B3495F39A7F7Q30235341-79A3B94C-60B7-46DE-AB38-4E7D04F10DBBQ30811550-D9D6AE1A-B299-4ABF-A0E9-3C971AA235CDQ33809045-01CC79C3-5447-4E6B-9B9A-6C8F2E9F55A2Q34212755-ACFD1F64-79E3-465C-ADC7-C46052969273Q34770459-3F91849C-02F5-4787-8AD8-BB2B6278AF41Q36031285-6F119325-11F1-4C91-BFD2-CD1C968F7B66Q36194054-24ECC4B6-F9D0-4B6B-81AC-341DBA3B6F76Q36195284-F55D5A7A-DDEC-4991-98AA-7957D5F3D934Q36205494-40DFEE37-1C12-46DC-9F54-71F209091FBCQ36334999-E9BCAC44-9E0C-4CC8-9C8F-1FDB87B07864Q36610390-29F47263-CA00-4342-A154-E708AFA80D58Q36796741-623E545D-0ADE-4A39-BB25-9F28466A29C6Q36819289-F62C9E1E-1162-48B0-87BA-8D5C09B53729Q37207756-5D48B47D-9E87-4865-AC1F-D51A02C551D1Q37267285-D67FEFA4-73BA-4102-BC23-06834DAE0D1BQ37301126-402D8992-37EA-4F9E-8675-7CCF8B961008Q37358271-54339F07-B7D9-4EA7-A36F-72E62D44CA9CQ37391811-BD36E257-C7FE-4A92-868F-5B00DE2D7861Q37465523-3F80522B-97D9-45F3-BC06-5F6F799927DDQ37536373-F8F01227-FD60-4344-92CB-4F9D143A7CF8Q37600477-3948B01C-A7D1-4646-81FC-DB76F73D88B4Q37738491-EDE1321B-9A5D-4594-8FFB-EFEDD8943B4DQ37987351-BA001451-0158-4C38-BB8C-4699A78FAD6DQ38065767-500CF94C-74DC-4744-A675-2C7480351246Q38092899-5C2DE4D2-CA53-429C-8036-64F3CA56DEC6Q38116472-98C0DEAC-397C-4923-8756-56921D423FE0Q38125240-CB8A403E-8B8D-4DB8-88EB-8629523C9C43Q38151938-A4638262-144A-4655-A947-B4A1A2C9631BQ38170177-FBB4A342-B484-4C39-A524-E2FBC95CE840Q38203622-21BD5E6B-E34C-40B1-A67D-6E662F1732AE
P2860
Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Subcutaneous abatacept versus ...... uate response to methotrexate.
@ast
Subcutaneous abatacept versus ...... uate response to methotrexate.
@en
type
label
Subcutaneous abatacept versus ...... uate response to methotrexate.
@ast
Subcutaneous abatacept versus ...... uate response to methotrexate.
@en
prefLabel
Subcutaneous abatacept versus ...... uate response to methotrexate.
@ast
Subcutaneous abatacept versus ...... uate response to methotrexate.
@en
P2093
P2860
P356
P1476
Subcutaneous abatacept versus ...... quate response to methotrexate
@en
P2093
A Covarrubias
C Legerton
J A Simon-Campos
M C Genovese
P2860
P304
P356
10.1002/ART.30463
P50
P577
2011-10-01T00:00:00Z